Updated Oct 14, 7:33 PM ET
Sangamo’s Chapter 11 has moved to implementing the PTC asset sale authorized by the September 2 sale order Dkt. 426, with $111 million in closing consideration and additional contingent payments. Resolving the remaining estate and distributions is the next restructuring task; the equity committee’s October 1 statement Dkt. 492 asserts that sale proceeds suffice to pay creditors in full and seeks lower administrative costs.
Motion1:00 PM ETDkt. 471Motion of Debtor for Entry of an Order Extending Period Within Which the Debtor May Remove Actions Pursuant to 28 U.S.C. § 1452 and Rule 9027 of the Federal Rules of Bankruptcy Procedure and Granting Related Relief [Hearing scheduled for 11/2/2026 at 01:00 PM at US Bankruptcy Court, 824 Market St., 3rd Fl., Courtroom #7, Wilmington, Delaware. Objections due by 10/5/2026.] (Filed by Sangamo Therapeutics, Inc.)
in 18 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchDebt-Free Sangamo Therapeutics Files Chapter 11 With $75M Sale Bids ·
Case facts and filing dates come from court records.